Carmona-Bayonas, Alberto; Jiménez-Fonseca, Paula; Lamarca, Ángela; Barriuso, Jorge; Castaño, Ángel; Benavent, Marta; Alonso, Vicente; Riesco-Martínez, María-del-Carmen; Alonso-Gordoa, Teresa; Custodio, Ana; Sánchez-Cánovas, Manuel; Hernando-Cubero, Jorge; López, Carlos; Lacasta, Adelaida; Fernández-Montes, Ana; Marazuela, Mónica; Crespo, Guillermo; Escudero, Pilar; Díaz, José-Ángel; Feliciangeli, Eduardo; Gallego, Javier; Llanos, Marta; Segura, Ángel; Vilardell, Felip; Percovich, Juan; Grande, Enrique; Capdevila, Jaume; Valle, Juan-W; García-Carbonero, Rocío
(LIPPINCOTT WILLIAMS & WILKINS, 2019-10-01)
PURPOSE: Somatostatin analogs (SSAs) are recommended for the first-line treatment of most patients with well-differentiated, gastroenteropancreatic (GEP) neuroendocrine tumors; however, benefit from treatment is heterogeneous. ...